Copyright
©The Author(s) 2015.
World J Hepatol. May 8, 2015; 7(7): 980-992
Published online May 8, 2015. doi: 10.4254/wjh.v7.i7.980
Published online May 8, 2015. doi: 10.4254/wjh.v7.i7.980
Interventions | Design | Start year | Main inclusion criteria | Primary outcomes | Registered No. | Status |
Immuncell-LC: activated T lymphocyte | Phase III | 2008 | Stage I and II, complete resection within 12 wk | Efficacy and safety | NCT00699816 | Completed |
CIK | Phase III | 2008 | After radical resection of HCC, no prior anti-cancer therapy | Time to recurrence | NCT01749865 | Recruiting |
CIK | Phase III | 2008 | After radical resection, no prior anti-cancer treatment | Time to recurrence | NCT00769106 | Recruiting |
Ex vivo expanded autologous immune killer cell, combined with TACE | Phase II/III | 2009 | Never receive TACE treatment, BCLC stage B and C | 2-yr reduction of tumor cells | NCT01024530 | Unknown |
NK cells, combined with liver transplantation | Phase I | 2010 | After liver transplantation for HCC | Side effect | NCT01147380 | Ongoing, but not recruiting |
Young TIL | Phase II | 2010 | Metastatic HCC with at least one lesion resectable | Tumor regression rate | NCT01174121 | Recruiting |
Autologous tumor infiltrating lymphocytes, combined with IL-2 | Phase I | 2011 | Metastatic HCC | Safety and tolerability | NCT01462903 | Unknown |
CIK, combined with Licartin | Phase IV | 2012 | Postoperative patients | 1-yr PFS | NCT01758679 | Recruiting |
Dendritic and cytokine-induced killer cells | Phase II | 2013 | After complete resection or TACE | PFS | NCT01821482 | Not yet recruiting |
CTL induced by DC loaded with multiple antigens | Phase I | 2013 | Complete tumor resection within 8 wk | 2-yr PFS and adverse events | NCT02026362 | Recruiting |
DC incubated with irradiated autologous tumor stem cells + GM-CSF | Phase I | 2013 | Candidates for HCC resection | Vital signs, physical examinations and adverse events | NCT01828762 | Completed |
Cord blood-derived CIK | Phase I | 2013 | After radical resection | Adverse events | NCT01914263 | Not yet recruiting |
Autologous NKT cells | Phase I | 2013 | Advanced HCC, refractory to standard treatments | Adverse events | NCT01801852 | Recruiting |
Immuncell-LC, combined with Nexavar | Phase II | 2013 | Stage III and IV, receiving or ready for Nexavar treatment | 2-yr PFS | NCT01897610 | Recruiting |
MG4101: ex vivo expanded allogeneic NK cell | Phase II | 2013 | Stage III, after curative resection | 1-yr DFS | NCT02008929 | Recruiting |
- Citation: Hong YP, Li ZD, Prasoon P, Zhang Q. Immunotherapy for hepatocellular carcinoma: From basic research to clinical use. World J Hepatol 2015; 7(7): 980-992
- URL: https://www.wjgnet.com/1948-5182/full/v7/i7/980.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i7.980